secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2022-03-17T23:59:59+00:00
Accession:  0001104659-22-034768
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE Therapeutics reports FY2021 revenue $14.8M, net loss $73.3M; pipeline progress
--------------------------------------------------------------------------------

- FY2021 revenue $14.8M (down 30% YoY); net loss $73.3M, adjusted net loss $65.2M; EPS -$1.42.
- FMX114 Phase 1b showed acceptable safety/PK; Phase 2a top-line results expected Q2 2022.
- VYN201 preclinical data in TH17, fibrosis, vitiligo models show significant improvement; IND/H2 2022.
- Divested MST franchise to Journey Medical for $20M upfront + $5M in 1 yr + up to $450M milestones.
- Prepaid $35M debt in Aug 2021; entered $30M equity purchase agreement with Lincoln Park Capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922034768/0001104659-22-034768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922034768/tm228420d5_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-034768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer